Abstract:The role of human epidermal growth factor receptor 2 (HER2) amplification as a biomarker for treatment in patients with lymph node (LN)-metastatic penoscrotal extramammary Paget's disease (EMPD) was investigated in the present study. A total of 11 male patients with LN-metastatic penoscrotal EMPD were retrospectively reviewed. Positron emission tomography/computed tomography (PET/CT) was conducted prior to surgery. Immunohistochemistry and fluorescence in situ hybridization were used to evaluate HER2 gene amplification in LN samples. Sanger sequencing was used to investigate HER2 mutations. A literature review of the prevalence of HER2 amplification in EMPD and the efficacy of HER2-targeted therapy was also undertaken. PET/CT is effective in detecting metastatic sites. The sensitivity and specificity of PET/CT was 90.9 and 100.0% for inguinal LNs, and 85.7 and 80.0% for pelvic LNs, respectively. The median time from LN dissection to disease progression was 15.9±1.5 months. Of the 11 patients, 3 (27.3%) indicated HER2 amplification. Patients with HER2 amplification showed shorter median times from disease discovery to LN metastasis (HER2 amplification vs HER2 non-amplification; 15.6 vs. 10.0 months; P=0.50) and from LN dissection to disease progression (HER2 amplification vs. HER2 non-amplification, 16.2 vs. 13.6 months; P=0.11). However, the aforementioned observations were not indicated to be statistically significant. No HER2 mutations were identified. Trastuzumab, a HER2-targeted monoclonal antibody, was administered to 2 of the patients with HER2 amplification. A literature review of the prevalence of HER2 amplification in EMPD and the efficacy of HER2-targeted therapy showed similar results. Altogether, 485 cases of EMPD were reported, 35 of which had metastases. The results in the present study suggest that PET/CT should be used on all metastatic EMPD patients. EMPD may be effectively treated with trastuzumab. The present study and case reports from the literature provide evidence for the benefit of testing for HER2 amplification in this rare disease and highlight the requirement for a multicenter clinical trial to assess the impact of trastuzumab therapy in treating this disease.

NECTIN4‐targeted antibody–drug conjugate is a potential therapeutic option for extramammary Paget disease

Immunotherapy May Be More Appropriate for ERBB2 Low-Expressing Extramammary Paget’s Disease Patients: a Prognosis Analysis and Exploration of Targeted Therapy and Immunotherapy of Extramammary Paget’s Disease Patients

Clinical Features and Follow Up Analysis of 19 Patients Wit Extramammary Paget Disease

KS-EMPD-1: a novel cell line of primary extramammary Paget's disease

Extramammary Paget's disease treated with of anti‐programmed cell death protein 1 therapy after docetaxel therapy failure

Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A

Immunotherapy may be more appropriate for ERBB2 low-expressing extramammary paget's disease patients: a prognosis analysis and exploration of targeted therapy and immunotherapy of extramammary paget's disease patients

FOXM1: a new therapeutic target of extramammary Paget disease

Untargeted Metabolomics Yields Insight into Extramammary Paget’s Disease Mechanisms

Human Epidermal Growth Factor Receptor 2 Amplification As a Biomarker for Treatment in Patients with Lymph Node-Metastatic Penoscrotal Extramammary Paget's Disease

Treatment of Metastatic Primary Extramammary Paget Disease with Combination Anlotinib and Tislelizumab: A Case Report and Review of the Literature

Establishment of a trastuzumab-resistant extramammary Paget disease model: loss of PTEN as a potential mechanism

Untargeted metabolomics yields insight into extramammary Paget's disease mechanisms

Targeted Therapeutic Strategies for Nectin-4 in Breast Cancer: Recent Advances and Future Prospects

Advanced Scrotal Extramammary Paget's Disease Treated with Apatinib: A Case Report.

Chemokine Receptors CXCR4 and CXCR7 are Associated with Tumor Aggressiveness and Prognosis in Extramammary Paget Disease.

Recent treatment and prognosis in 643 patients with extramammary Paget's disease

Clinicopathological Characteristics, Management and Outcome of Metastatic Penoscrotal Extramammary Paget's Disease

Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC) therapy.

Oncogenic Mutations In Extramammary Paget'S Disease And Their Clinical Relevance

Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer